

Neurology Grand Rounds

The University of Oklahoma Health Sciences Center

"Idiopathic Intracranial Hypertension"

James O'Brien, MD
Assistant Professor
Neuro-Ophthalmology
Department of Ophthalmology

February 4, 2020

8:00 am

Rainbolt Auditorium at Samis Education Center, 2nd Level
The Children's Hospital, 1200 Children's Avenue

Acknowledgement of Commercial and In-Kind Support: This activity received no commercial or in-kind support.

Professional Practice Gap:

1. Idiopathic intracranial hypertension (IIH) is an incompletely-understood, increasingly common condition which reduces quality of life and is **potentially blinding**.
2. Patients with IIH frequently require the care from a multi-disciplinary physician team.
3. It is therefore important for all physicians – particularly neurologists, ophthalmologists and neurosurgeons – to be knowledgeable of this entity in order to enable early diagnosis and treatment.

Learning Objectives: Upon completion of this series, participants will improve their competence and performance by being able to:

1. Discuss the diagnostic criteria for IIH.
2. Describe risk factors for and associations of IIH.
3. Discuss the typical and atypical signs and symptoms of IIH.
4. Describe the Frisen papilledema grading systems.
5. Explain the work-up and management options for IIH patients.



PLEASE POST



Disclaimer Statement:

Statements, opinions and results of studies contained in the program are those of the presenters and authors and do not reflect the policy or position of the Board of Regents of the University of Oklahoma ("OU") nor does OU provide any warranty as to their accuracy or reliability.

Every reasonable effort has been made to faithfully reproduce the presentations and material as submitted. However, no responsibility is assumed by OU for any claims, injury and/or damage to persons or property from any cause, including negligence or otherwise, or from any use or operation of any methods, products, instruments or ideas contained in the material herein.

Policy on Faculty and Presenter Disclosure:

It is the policy of the University of Oklahoma College of Medicine that the faculty and presenters disclose real or apparent conflicts of interest relating to the topics of this educational activity, and also discloses discussions of unlabeled/unapproved uses of drugs or devices during their presentation(s).

Accreditation Statement:

The University of Oklahoma College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Oklahoma College of Medicine designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Conflict Resolution Statement:

The University of Oklahoma College of Medicine, Office of Continuing Professional Development has reviewed this activity's speaker and planner disclosures and resolved all identified conflicts of interest, if applicable.

Nondiscrimination Statement:

The University of Oklahoma, in compliance with all applicable federal and state laws and regulations, does not discriminate on the basis of race, color, national origin, sex, sexual orientation, genetic information, gender identity, gender expression, age, religion, disability, political beliefs, or status as a veteran in any of its policies, practices or procedures. This includes, but is not limited to: admissions, employment, financial aid and educational services. Inquiries regarding non-discrimination policies may be directed to: Bobby J. Mason, Institutional Equity Officer, (405) 325-3546, bjm@ou.edu, or visit www.ou.edu/eoo.

Accommodation Statement: For accommodation, please contact Brigitte Nettles at 271-4113.

Disclosure & Resolution Report

The University of Oklahoma College of Medicine and the Irwin H. Brown Office of Continuing Professional Development must ensure balance, independence, objectivity and scientific rigor in all its activities. We have implemented a process where everyone who is in a position to control the content of an educational activity has disclosed to us all relevant financial relationships with any commercial interest. In addition, should it be determined that a conflict of interest exists as a result of a financial relationship one may have, this will be resolved prior to the activity. This policy is designed to provide the target audience with an opportunity to review any affiliations between the CME organizers and presenters and supporting organizations for the purpose of determining the potential presence of bias or influence over educational content. The following is a summary of this activities disclosure information.

Role	First Name	Last Name	Nature of Relevant Financial Relationship	
			Commercial Interest	What was received?
Course Director	Fahd	Sultan, MD	I have no relevant financial relationships or affiliations with commercial interests to disclose.	
Course Contact	Brigitte	Nettles	I have no relevant financial relationships or affiliations with commercial interests to disclose.	
Planning Committee	Ahmad	Al-Awwad, MD	I have no relevant financial relationships or affiliations with commercial interests to disclose.	
Planning Committee/ Moderator/Speaker	David Lee	Gordon, MD	I have no relevant financial relationships or affiliations with commercial interests to disclose.	
Planning Committee	Roohi	Katyal, MD	I have no relevant financial relationships or affiliations with commercial interests to disclose.	
Planning Committee	Gina	Perez Giraldo, MD	I have no relevant financial relationships or affiliations with commercial interests to disclose.	
Speaker	James	O'Brien, MD	I have no relevant financial relationships or affiliations with commercial interests to disclose.	

Dr. O'Brien will be discussing experimental or off-label drugs and therapies that have not been approved by the FDA.